Xcout Intel
Actio Biosciences competitors & alternatives
The 12 closest competitors and alternatives to Actio Biosciences among biotechnology companies — ranked by similarity to what Actio Biosciences actually does, not by market-cap band.
Subscribe to see Actio Biosciences’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Actio Biosciences
Actio Biosciences is a privately held biotechnology company utilizing genomic medicine to discover and develop treatments for rare diseases and epilepsy.
Actio Biosciences at a glance
Actio Biosciences is a biotechnology company headquartered in United States. Its most recent funding round, Series B, raised $66M in June 2025. Xcout tracks 16 named people at Actio Biosciences, including Sunil Sahdeo (Chief Operating Officer).
Actio Biosciences leadership
- Sunil SahdeoChief Operating Officer
- Cayce DentonChief Financial Officer
- David BreckenridgeChief Scientific Officer
- Pete CondonChief Business Officer
- David GoldsteinCEO, Co-founder
- John McHutchisonCo-founder
10 more named people on record for Actio Biosciences, with roles, board committees and tenure — see the full roster →
Actio Biosciences funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $66M | 5 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Recent Actio Biosciences news
- AcquisitionJazz Pharmaceuticals Completes Acquisition of Actio Biosciences
- AcquisitionJazz Pharmaceuticals Completes Acquisition of Actio Biosciences - PR Newswire
- AcquisitionJazz Pharmaceuticals to acquire Actio Biosciences for $820 million, expanding rare epilepsy portfolio - CNBC
- AcquisitionJazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio - PR Newswire
Top 12 Actio Biosciences competitors
Ranked by semantic similarity — how close each company is to Actio Biosciences by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotech
Addition Therapeutics is a biotechnology research company based in South San Francisco, California. The firm is on a mission to fulfill the promise of genomic medicine for chronic and rare diseases, having emerged from stealth with significant funding.
Similar biotechnology company
Neuron23 is a biotechnology company founded in 2018 that focuses on developing precision therapeutics for genetic diseases. Headquartered in South San Francisco, California, the company relies on a team of scientific experts and entrepreneurs.
Similar biotechnology company
Vico Therapeutics is a neurology genetic medicine and biotechnology company pioneering targeted treatments for devastating disorders from its location at the BioScience Park.
Similar biotechnology company
Gemma Labs Inc. (GEMMABio) is a biotechnology company that develops gene therapies for rare diseases using next-generation AAV technology. The company focuses on programs targeting motor neuron disorders, skeletal conditions, and cardiomyopathies to serve the rare disease community.
Biotech
Character Biosciences is a biotechnology company that uses human genetics and functional genomics to discover and develop precision medicines. Its work has focused particularly on genetically informed therapies for age-related diseases, including ophthalmic conditions such as age-related macular degeneration.
Similar biotechnology company
Arbor Biotechnologies, Inc. is a next-generation gene editing company focused on discovering and developing precise genetic medicines for rare and complex diseases.
Similar biotechnology company
Scenic Biotech is a biotechnology company headquartered in Amsterdam, Netherlands, that advances modifier therapy as an approach to treating genetic disorders by uncovering novel genome pathways.
Biotech
Variant Bio, Inc. is a biotechnology company that uses human genomic diversity and population genetics to discover therapeutic targets and develop medicines. It works with researchers, healthcare and biotechnology partners, and genetically diverse communities to study traits associated with health and disease.
Biotech
Stoke Therapeutics, Inc. is an emerging biopharmaceutical company dedicated to developing innovative antisense oligonucleotide (ASO) therapies. Its primary focus is to target and address the fundamental causes of severe genetic disorders, particularly within the United States. The company employs its exclusive Targeted Augmentation of Nuclear Gene Output (TANGO) platform to engineer ASOs that precisely enhance protein expression. Stoke's most advanced candidate, STK-001, is currently progressing through Phase I/IIa clinical trials for Dravet syndrome, a severe and debilitating genetic epilepsy. Additionally, STK-002 is in the preclinical development stage for treating autosomal dominant optic atrophy. The company has also established a licensing and collaborative agreement with Acadia Pharmaceuticals Inc. to identify, develop, and market new RNA-based medicines for critical and rare genetic neurodevelopmental conditions impacting the central nervous system. Formerly known as ASOthera Pharmaceuticals, Inc., the company rebranded to Stoke Therapeutics, Inc. in May 2016. Founded in 2014, Stoke Therapeutics, Inc. maintains its headquarters in Bedford, Massachusetts.
Similar biotechnology company
Coave Therapeutics is a clinical-stage biotechnology company headquartered in Paris, France. The company focuses on developing life-changing gene therapies targeting rare ocular and central nervous system diseases.
Similar biotechnology company
Exsilio Therapeutics Inc. is a biotechnology company headquartered in Boston, Massachusetts, founded in 2022 to pioneer genomic medicines and advanced genetic therapies.
Biotech
Verge Genomics develops a proprietary AI and machine learning platform utilizing human brain data to transform neuroscience drug discovery and precision neurology. The company provides foundation models and analytical tools to pharmaceutical and biotechnology developers for target discovery, biomarker identification, and clinical trial patient stratification.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Actio Biosciences and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Actio Biosciencesand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →